
Michele Ardolino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9150983/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. Journal of Clinical Investigation, 2018, 128, 4654-4668.	3.9	591
2	Neutrophils Suppress Intraluminal NK Cell–Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. Cancer Discovery, 2016, 6, 630-649.	7.7	369
3	p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. Journal of Experimental Medicine, 2013, 210, 2057-2069.	4.2	314
4	Recognition of Tumors by the Innate Immune System and Natural Killer Cells. Advances in Immunology, 2014, 122, 91-128.	1.1	296
5	Killers 2.0: NK cell therapies at the forefront of cancer control. Journal of Clinical Investigation, 2019, 129, 3499-3510.	3.9	166
6	Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. Journal of Clinical Investigation, 2014, 124, 4781-4794.	3.9	161
7	NK cell self tolerance, responsiveness and missing self recognition. Seminars in Immunology, 2014, 26, 138-144.	2.7	160
8	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. Frontiers in Immunology, 2020, 11, 1512.	2.2	126
9	DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK–T cell interaction. Blood, 2011, 117, 4778-4786.	0.6	118
10	Immunosurveillance and immunotherapy of tumors by innate immune cells. Current Opinion in Immunology, 2016, 38, 52-58.	2.4	85
11	Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. Blood, 2009, 113, 2955-2964.	0.6	66
12	NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses. Frontiers in Immunology, 2012, 3, 408.	2.2	53
13	Immunotherapy for sarcomas: new frontiers and unveiled opportunities. , 2021, 9, e001580.		48
14	A Role for Host Activation-Induced Cytidine Deaminase in Innate Immune Defense against KSHV. PLoS Pathogens, 2013, 9, e1003748.	2.1	41
15	When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer. Science Advances, 2022, 8, eabj3286.	4.7	35
16	Characterization of a novel NKG2D and NKp46 double-mutant mouse reveals subtle variations in the NK cell repertoire. Blood, 2013, 121, 5025-5033.	0.6	31
17	Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver. European Journal of Immunology, 2021, 51, 2568-2575.	1.6	28
18	Cytokine treatment in cancer immunotherapy. Oncotarget, 2015, 6, 19346-19347.	0.8	17

MICHELE ARDOLINO

#	Article	IF	CITATIONS
19	ls innate immunity our best weapon for flattening the curve?. Journal of Clinical Investigation, 2020, 130, 3954-3956.	3.9	11
20	Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors. OncoImmunology, 2016, 5, e1002725.	2.1	10
21	Loss of the Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers. Oncogene, 2020, 39, 4592-4602.	2.6	8
22	Differential Role of Hematopoietic and Nonhematopoietic Cell Types in the Regulation of NK Cell Tolerance and Responsiveness. Journal of Immunology, 2016, 197, 4127-4136.	0.4	5
23	Muscle-specific deletion of SLK/Stk2 enhances p38 activity and myogenesis in mdx mice. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118917.	1.9	5
24	Modulation of T Cell-Mediated Immune Responses by Natural Killer Cells. , 2010, , 315-327.		4
25	A New Functional Screening Platform Identifies Colistin Sulfate as an Enhancer of Natural Killer Cell Cytotoxicity. Cancers, 2022, 14, 2832.	1.7	0